Nishadil
Signup Signin
Delhi | 25°C (windy)
A Lethal Betrayal: Unmasking the Global Crisis of Killer Cough Syrups and India's Regulatory Blind Spot

A Lethal Betrayal: Unmasking the Global Crisis of Killer Cough Syrups and India's Regulatory Blind Spot
US BioSecure Act Ignites Indian Pharma: A New Era for CDMOs

US BioSecure Act Ignites Indian Pharma: A New Era for CDMOs
Indian Pharma Soars: US BIOSECURE Act Triggers Major Opportunity Shift

Indian Pharma Soars: US BIOSECURE Act Triggers Major Opportunity Shift
White House Shelves Generic Drug Tariffs, Paving the Way for Indian Pharma's Continued Success

White House Shelves Generic Drug Tariffs, Paving the Way for Indian Pharma's Continued Success
Trump's Trade Winds: Navigating the Storm for India's Pharma Giants

Trump's Trade Winds: Navigating the Storm for India's Pharma Giants
Indian Pharma's Unwavering Allure: Why Mutual Funds Are Doubling Down Amidst Global Headwinds

Indian Pharma's Unwavering Allure: Why Mutual Funds Are Doubling Down Amidst Global Headwinds
Major Setback: Indian Pharma Giants Recall Thousands of Drug Batches in US Over Manufacturing Flaws

Major Setback: Indian Pharma Giants Recall Thousands of Drug Batches in US Over Manufacturing Flaws
Trump's Tariff Threat Looms: How India's Pharma Giants Brace for a 100% Import Duty Shake-up

Trump's Tariff Threat Looms: How India's Pharma Giants Brace for a 100% Import Duty Shake-up
Trump's Bold Move: 100% Tariff on Branded Drugs Set to Shake Global Pharma, What It Means for India

Trump's Bold Move: 100% Tariff on Branded Drugs Set to Shake Global Pharma, What It Means for India
Trump's Tariffs and Indian Pharma: A Looming Cloud of Uncertainty Over Specialty Drugs

Trump's Tariffs and Indian Pharma: A Looming Cloud of Uncertainty Over Specialty Drugs
Unlocking India's Pharmaceutical Potential: A Strategic Blueprint for Self-Reliance and Innovation

Unlocking India's Pharmaceutical Potential: A Strategic Blueprint for Self-Reliance and Innovation
Indian Pharma Sector Poised for Massive Rs 45,000 Crore Investment Boom by FY26, ICRA Reports

Indian Pharma Sector Poised for Massive Rs 45,000 Crore Investment Boom by FY26, ICRA Reports
Indian Pharma Exporters Grapple with Multi-Million Dollar Payment Delays from Egyptian Firm

Indian Pharma Exporters Grapple with Multi-Million Dollar Payment Delays from Egyptian Firm
Unlocking Potential: Why Glenmark Pharma is Poised for a Massive Upswing

Unlocking Potential: Why Glenmark Pharma is Poised for a Massive Upswing
Glenmark Pharma: Why Analysts Are Sounding the Alarm Bells

Glenmark Pharma: Why Analysts Are Sounding the Alarm Bells
Load more..